Your browser doesn't support javascript.
loading
Structure-based discovery of dual pathway inhibitors for SARS-CoV-2 entry.
Wang, Haofeng; Yang, Qi; Liu, Xiaoce; Xu, Zili; Shao, Maolin; Li, Dongxu; Duan, Yinkai; Tang, Jielin; Yu, Xianqiang; Zhang, Yumin; Hao, Aihua; Wang, Yajie; Chen, Jie; Zhu, Chenghao; Guddat, Luke; Chen, Hongli; Zhang, Leike; Chen, Xinwen; Jiang, Biao; Sun, Lei; Rao, Zihe; Yang, Haitao.
  • Wang H; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
  • Yang Q; Shanghai Clinical Research and Trial Center, Shanghai, P.R. China.
  • Liu X; Guangzhou Laboratory, Guangzhou, China.
  • Xu Z; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
  • Shao M; Shanghai Clinical Research and Trial Center, Shanghai, P.R. China.
  • Li D; School of Physical Science and Technology, ShanghaiTech University, Shanghai, China.
  • Duan Y; University of Chinese Academy of Sciences, Beijing, China.
  • Tang J; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
  • Yu X; Shanghai Clinical Research and Trial Center, Shanghai, P.R. China.
  • Zhang Y; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
  • Hao A; Shanghai Clinical Research and Trial Center, Shanghai, P.R. China.
  • Wang Y; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
  • Chen J; Shanghai Clinical Research and Trial Center, Shanghai, P.R. China.
  • Zhu C; Guangzhou Laboratory, Guangzhou, China.
  • Guddat L; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
  • Chen H; University of Chinese Academy of Sciences, Beijing, China.
  • Zhang L; CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
  • Chen X; The Fifth People's Hospital of Shanghai, Shanghai Institute of Infectious Disease and Biosecurity, and Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
  • Jiang B; The Fifth People's Hospital of Shanghai, Shanghai Institute of Infectious Disease and Biosecurity, and Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
  • Sun L; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
  • Rao Z; Shanghai Clinical Research and Trial Center, Shanghai, P.R. China.
  • Yang H; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Nat Commun ; 14(1): 7574, 2023 Nov 21.
Article en En | MEDLINE | ID: mdl-37990007
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article